In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells.

@article{Bijsterbosch1997InVF,
  title={In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells.},
  author={M. Bijsterbosch and M. Manoharan and E. T. Rump and R. D. de Vrueh and R. van Veghel and K. Tivel and E. Biessen and C. Bennett and P. D. Cook and T. V. van Berkel},
  journal={Nucleic acids research},
  year={1997},
  volume={25 16},
  pages={
          3290-6
        }
}
Systemically administered phosphorothioate antisense oligodeoxynucleotides can specifically affect the expression of their target genes, which affords an exciting new strategy for therapeutic intervention. Earlier studies point to a major role of the liver in the disposition of these oligonucleotides. The aim of the present study was to identify the cell type(s) responsible for the liver uptake of phosphorothioate oligodeoxynucleotides and to examine the mechanisms involved. In our study we… Expand
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver.
Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Pharmacokinetics of Antisense Oligonucleotides
Renal uptake of an 18-mer phosphorothioate oligonucleotide.
Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo.
In vivo studies with antisense oligonucleotides.
Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
...
1
2
3
4
5
...